{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T20:09:57Z","timestamp":1772914197243,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bulcan.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T12:18:04Z","timestamp":1637324284000},"page":"S98-S103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S","title":["Complications des cellules CAR-T autres que les infections, CRS et ICANS\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"108","author":[{"given":"C\u00e9cile","family":"Pochon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Courbon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franciane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Picard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Sterin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Tudesq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.10.004_bib0155","article-title":"Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CART cells): recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"4","author":"Alsuliman","year":"2021","journal-title":"Bull Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2021.10.004_bib0160","first-page":"664","article-title":"Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia","volume":"16","author":"Maude SL:","year":"2018","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2021.10.004_bib0165","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2021.10.004_bib0170","first-page":"159","article-title":"Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials","volume":"68","author":"Yassine","year":"2020","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.bulcan.2021.10.004_bib0175","first-page":"17","article-title":"Treatment with anti-CD19\u00a0chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia","volume":"68","author":"Danylesko","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"5","key":"10.1016\/j.bulcan.2021.10.004_bib0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/CCO.0000000000000667","article-title":"Clinical data, limitations and perspectives on chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"32","author":"Beauvais","year":"2020","journal-title":"Curr Opin Oncol"},{"issue":"25","key":"10.1016\/j.bulcan.2021.10.004_bib0185","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bulcan.2021.10.004_bib0190","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T Cell therapy: cross-sectional FDA adverse events reporting system analysis","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.bulcan.2021.10.004_bib0195","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.bbmt.2018.05.014","article-title":"Cardiac profile of chimeric antigen receptor T Cell therapy in children: a single-institution experience","volume":"24","author":"Burstein","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.bulcan.2021.10.004_bib0200","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.bulcan.2021.10.004_bib0205","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19\u00a0CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.bulcan.2021.10.004_bib0210","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bulcan.2021.10.004_bib0215","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bulcan.2021.10.004_bib0220","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.bulcan.2021.10.004_bib0225","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19\u00a0CAR-T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.bulcan.2021.10.004_bib0230","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"106","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bulcan.2021.10.004_bib0235","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX. A model for CAR T-cell related hematological toxicity in relapsed\/refractory large B-cell lymphoma","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2021.10.004_bib0240","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.17121","article-title":"Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed\/refractory large B-cell lymphoma","volume":"192","author":"Lutfi","year":"2021","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.bulcan.2021.10.004_bib0245","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.10.004_bib0250","doi-asserted-by":"crossref","first-page":"573822","DOI":"10.3389\/fonc.2020.573822","article-title":"Acute graft-versus-host disease after humanized anti-CD19-CAR-T therapy in relapsed B-ALL patients after allogeneic hematopoietic stem cell transplant","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2021.10.004_bib0255","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17737","article-title":"Graft-versus-host disease induced by tisagenlecleucel in patients after allogeneic stem cell transplantation","author":"Gabelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"11S","key":"10.1016\/j.bulcan.2021.10.004_bib0260","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2021.10.004_bib0265","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden","year":"2019","journal-title":"Curr Res Transl Med"},{"issue":"2","key":"10.1016\/j.bulcan.2021.10.004_bib0270","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2021.10.004_bib0275","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"25","key":"10.1016\/j.bulcan.2021.10.004_bib0280","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.jacc.2019.10.028","article-title":"Chimeric antigen receptor T-cells and cardiovascular toxicity: cause for concern?","volume":"74","author":"Lancellotti","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.bulcan.2021.10.004_bib0285","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41409-020-01006-x","article-title":"G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma","volume":"55","author":"Galli","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2021.10.004_bib0290","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1097\/HS9.0000000000000545","article-title":"Hematologic rescue of CAR T-cell-mediated prolonged pancytopenia using autologous peripheral blood hematopoietic stem cells in a lymphoma patient","volume":"5","author":"Godel","year":"2021","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.bulcan.2021.10.004_bib0295","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/bjh.15012","article-title":"CD34(+) selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation","volume":"180","author":"Mainardi","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2021.10.004_bib0150","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jmii.2021.02.006","article-title":"Potential role of tocilizumab in severe gastrointestinal barrier damage after CAR T-cell therapy","volume":"54","author":"Beauvais","year":"2021","journal-title":"J Microbiol Immunol Infect"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121004458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121004458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:06Z","timestamp":1757792106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121004458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0007455121004458"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.10.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complications des cellules CAR-T autres que les infections, CRS et ICANS\u00a0: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}